期刊文献+

浅谈瑞舒伐他汀降脂及消退颈动脉血管斑块疗效 被引量:1

下载PDF
导出
摘要 目的:探讨瑞舒伐他汀对混合型高脂血症合并颈动脉血管粥样斑块的疗效及安全性。方法:将本院收住的高脂血症合并颈动脉血管粥样斑块的患者128例,采用随机表法分为治疗组64例和对照组64例两组,治疗组口服瑞舒伐他汀10mg6个月,检测治疗前后血脂水平和颈动脉血管粥样斑块消退疗效及安全性;对照组给予辛伐他汀10mg每晚口服。结果:治疗组治疗后甘油三酯、胆固醇、低密度脂蛋白水平明显低于治疗前,高密度脂蛋白明显高于治疗前,颈动脉血管斑块面积,颈动脉血管内膜-中层厚度(TMT)明显小于治疗前及对照组(均P<0.05)。结论:瑞舒伐他汀调节血脂及消退颈动脉血管斑块,改善颈动脉血管粥样硬化疗效确切。
作者 郭迎霞
出处 《北方药学》 2018年第2期157-158,共2页 Journal of North Pharmacy
  • 相关文献

参考文献4

二级参考文献32

  • 1李霞,周智广,亓海英,陈小燕,黄干.用空腹C肽代替胰岛素改良Homa公式评价胰岛素抵抗和胰岛β细胞功能[J].中南大学学报(医学版),2004,29(4):419-423. 被引量:211
  • 2Steven E. Nissen,Stephen J. Nicholls,Ilks Sipahi,Peter Libby,Joel S. Raichlen,Christie M. Ballantyne,Jean Davignon,Raimund Erbel,Jean Charles Fruchart,Jean-Claude Tardif,Paul Schoenhagen,Tim Crowe,Valerie Cain,Kathy Wolski,Marlene Coormastic,E. Murat Tuzcu,仝其广(译),王淑敏(译),胡大一(校).极高强度他汀治疗对冠状动脉粥样硬化消退的影响——ASTEROID试验[J].美国医学会杂志(中文版),2006,25(4):215-223. 被引量:346
  • 3DESCAMPS O S, DE BACKER G, ANNEMANS L, et al. New European guidelines for the management of dyslipidaemia in cardiovascular prevention [J]. Rev Med Liege, 2012,67 : 118-- 127.
  • 4SULISTYONINGRUM D C, SINGH R, DEVLIN A MI Epigenetic regulation of glucocorticoid receptor expression in aorta from mice with hyperhomocys- teinemia[J]. Epigenetics, 2012,7 : 514 -- 521.
  • 5BACCARELLI A, RIENSTRA M, BENJAMIN.E J. Cardiovascular epigenetics: basic concepts and results from animal and human studies[J]. Circ Cardiovasc Genet, 2010,3 : 567--573.
  • 6CASTRO R, RIVERA I, STRUYS E A, et al. In- creased homocys-teine and S-adenosylhomocysteine concentrations and DNA hy-pomethylation in vascular disease[J]. Clin Chem, 2003,49 : 1292-1296.
  • 7ROSENSON R S. Rosuvastatin: a new inhibitor of HMG-CoA reductase for the treatment of dyslipidemia [J]. Expert Rev Cardiovasc Ther, 2003,1 : 495 -- 505.
  • 8KOUBAA N, NAKBI A, SMAOUI M, et al. Hy- perhomocysteinemia and elevated ox-LDL in Tunisian type 2 diabetic patients: role Of genetic and dietary factors[J]. Clin Biochem, 2007,40 : 1007-- 1014.
  • 9BRESSLER J, SHIMMIN L C, BOERWINKLE E, et al. Global DNA methylation and risk of subclinical atberosclerosis in young adults., the Pathobiological Determinants of Atherosclerosis in Youth (PDAY) study[J]. Atherosclerosis, 2011,219 : 958 -- 962.
  • 10CARTER N J. Rosuvastatin: a review of its use in the prevention of cardiovascular disease in apparently healthy women or men with normal LDL-C levels and elevated hsCRP levels[J]. Am J Cardiovasc Drugs, 2010,10:383--400.

共引文献29

同被引文献14

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部